Novartis’ Fabhalta® (iptacopan) has met its Phase III primary endpoint, demonstrating a significant slowing of kidney function decline in patients with IgA nephropathy (IgAN). This is a major positive development for patients suffering from this rare kidney disease and for Novartis, potentially leading to a new blockbuster drug. The drug’s efficacy in preserving kidney function offers significant therapeutic value. Investors should view this news favorably, as it points to strong future revenue potential for Novartis. However, the long-term effectiveness, side effects, and market access of the drug will be critical factors. The success of Fabhalta® could also spur further research and development in the treatment of IgAN and other proteinuric kidney diseases.